title: Resisting resistance: Establishing new treatment options for CRPC patients.
abstract: Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.
authors.affiliation: a Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health Bethesda , Maryland , USA.
authors.forename: Shaunna
authors.initials: S
authors.lastname: Beedie
authors.affiliation: a Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health Bethesda , Maryland , USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*
keywords: abiraterone; enzalutamide; prostate cancer; ▵4-abiraterone
references.citation: Prostate. 2015 May;75(7):777-82
references.pmid: 25731771
references.citation: Nature. 2015 Jul 16;523(7560):347-51
references.pmid: 26030522
references.citation: J Med Chem. 1995 Jun 23;38(13):2463-71
references.pmid: 7608911
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73
references.pmid: 7918112
references.citation: Eur Urol. 2015 Mar;67(3):470-9
references.pmid: 25306226